Wegovy maker Novo Nordisk's board slims down
Digest more
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...
Novo Nordisk faces leadership turmoil as its chairman and six board members resign amid disputes with the controlling ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
The maker of the popular weight-loss drug Wegovy announced on Wednesday that it will be cutting 9,000 jobs in the company. Novo Nordisk said a majority of the jobs lost, 5,000 of them, will be ...
LONDON/COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk has laid off dozens of employees at the largest U.S. manufacturing ...
Zacks Investment Research on MSN
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster ...
The overhaul comes after the foundation ousted former chief executive Lars Fruergaard Jørgensen in May, blaming him for an ...
LONDON (Reuters) -Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback